Comparison of Contoura Vision Outcomes Programmed Using the Manifest Refraction Verses Using Phorcides Planning Software in Patients With Oblique Astigmatism

Sponsor
Bismarck Lasik (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05888337
Collaborator
Sengi (Industry)
53
1
17.6
3

Study Details

Study Description

Brief Summary

The objective is to compare the percentage of monocular UDVA -0.1 logMAR (20/16) outcomes for each planning strategy (Phorcides and manifest refraction) at the 3-month post operative visit.

Condition or Disease Intervention/Treatment Phase
  • Device: Contoura LASIK with Phorcides planning strategy
  • Device: Contoura LASIK with manifest refraction planning strategy

Detailed Description

This study is a randomized, prospective contralateral eye study of visual outcomes in eyes planned with Phorcides compared to eyes planned using the manifest refraction after successful bilateral LASIK surgery. Subjects will be assessed pre-operatively, operatively and at 3 months postoperatively. Clinical evaluations will include measurement of visual acuity, manifest refraction, and administration of a questionnaire.

Study Design

Study Type:
Observational
Anticipated Enrollment :
53 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Comparison of Contoura Vision Outcomes Programmed Using the Manifest Refraction Verses Using Phorcides Planning Software in Patients With Oblique Astigmatism
Anticipated Study Start Date :
Jun 15, 2023
Anticipated Primary Completion Date :
Dec 1, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Contoura LASIK with Phorcides planning strategy

Device: Contoura LASIK with Phorcides planning strategy
Bilateral treatment with topography guided LASIK

Contoura LASIK with manifest refraction planning strategy

Device: Contoura LASIK with manifest refraction planning strategy
Bilateral treatment with topography guided LASIK

Outcome Measures

Primary Outcome Measures

  1. Percentage of eyes with monocular UDVA of logMAR -0.10 (20/16) in each group [3 months postoperatively]

Secondary Outcome Measures

  1. Percentage of eyes with monocular UDVA of logMAR -0.20 (20/12.5) in each group [3 months postoperatively]

Other Outcome Measures

  1. Percentage of eyes with monocular UDVA of logMAR 0.00 (20/20) in each group [3 months postoperatively]

  2. Mean/SD of residual refractive error and centroid of manifest refraction (dioptric magnitude of residual astigmatism and residual SE) [3 months postoperatively]

  3. Percentage of eyes with postoperative UDVA equal to or better than their preoperative CDVA [3 months postoperatively]

  4. Percentage of eyes that gained 1 or more lines postoperative CDVA and preoperative CDVA [3 months postoperatively]

  5. Percentage of subjects that report overall visual preference of the Phorcides planned eye vs manifest refraction planned eye [3 months postoperatively]

  6. Quantitative rating of overall satisfaction of vision in each eye [3 months postoperatively]

    Satisfaction will be measured using a questionnaire. Subjects will rate satisfaction with vision in each eye using the scale: Completely Dissatisfied Very Dissatisfied Somewhat Dissatisfied Somewhat Satisfied Very Satisfied Completely Satisfied

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • 18 years old and above

  • Preoperative total corneal Pachymetry 490um or above

  • BCVA 20/20 or better

  • Stable refractive error <0.50D MRSE change in preceding year

  • Good general and ocular health

  • Preoperative exam completed within three months of surgery

  • Soft contact lens wear discontinued 3 days prior to preoperative exam and the procedure

  • Residual stromal bed greater than 270um

  • Candidates who qualify for Contoura treatment OU (≤ -8.0 D SPH and ≤ -3.0 D CYL)

  • Candidates who elect to target both eyes targeted for emmetropia

  • ≤ -3.0 D Oblique astigmatism as defined as an axis between 30-60 degrees or between 120-150 degrees

Exclusion Criteria:
  • Subjects with usual relative and absolute contraindications for LASIK surgery (subjects with severe dry eye, subjects with recurrent corneal erosion, subjects with uncontrolled Glaucoma, subjects with collagen vascular disorders, keratoconus or signs of keratoconus, Uncontrolled Diabetes, Herpes, corneal dystrophies or degeneration; any irregular astigmatism)

  • Pachymetry below 490

  • Autoimmune or immunodeficiency diseases, Pregnant or nursing women

  • Subjects with signs of inability to understand consent for study and procedure planned

  • Subjects with history of previous ocular surgery

The principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.

Pregnancy has a known effect on the stability of refractions and visual acuity. As such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Bismarck Lasik Bismarck North Dakota United States 58501

Sponsors and Collaborators

  • Bismarck Lasik
  • Sengi

Investigators

  • Principal Investigator: Stephen A Wexler, MD, Bismarck Lasik

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Bismarck Lasik
ClinicalTrials.gov Identifier:
NCT05888337
Other Study ID Numbers:
  • SW-23-01
First Posted:
Jun 5, 2023
Last Update Posted:
Jun 5, 2023
Last Verified:
May 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 5, 2023